This trial is testing two different experimental treatments for small cell lung cancer that has returned after one other treatment. One experimental treatment is a single drug, and the other experimental treatment is a combination of two drugs. The trial will compare how well the experimental treatments work to a standard treatment.
- Small Cell Lung Cancer Relapse
1 Primary · 8 Secondary · Reporting Duration: At baseline and every six weeks (± one week) until end of treatment, up to 39 months
Side Effects for
3 Treatment Groups
1 of 3
Lurbinectedin plus Irinotecan
1 of 3
1 of 3
705 Total Participants · 3 Treatment Groups
Primary Treatment: Irinotecan · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 15 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there other ways in which Irinotecan has been studied?
"663 clinical trials have been completed for irinotecan since 2002, when it was first studied at Mayo Clinic. As of now, there are 336 active studies being conducted, a large portion of which are based in Toronto and North Carolina." - Anonymous Online Contributor
Are there vacancies in this trial for new participants?
"Yes, this clinical trial is still looking for participants. The most recent update on clinicaltrials.gov was on November 3rd, 2022 and the trial was originally posted on July 22nd of the same year." - Anonymous Online Contributor
What has been the most common side effect in people who have taken Irinotecan?
"There is some clinical evidence to support the efficacy of irinotecan, as well as numerous rounds of data collected to support its safety. Consequently, we have rated irinotecan as a 3 on our safety scale." - Anonymous Online Contributor
At how many different hospitals is this clinical trial taking place?
"University Health Network - Princess Margaret Hospital in Toronto, North Carolina, FirstHealth Outpatient Cancer Center in Pinehurst, Illinois, and McGill University Health Centre (MUHC) in Montréal, Massachusetts are all locations where this study is recruiting patients. In addition, there are 6 other sites." - Anonymous Online Contributor
What conditions does Irinotecan treat most often?
"Most often, irinotecan is used to treat leukemia, myelocytic, and acute conditions. However, it has also been known to be effective in treating colorectal carcinoma, ovarian cancer, and sarcoma." - Anonymous Online Contributor